Core Alternative Capital Sells 3,124 Shares of Eli Lilly and Company $LLY

Key Points

• Core Alternative Capital cut its stake in Eli Lilly by 26.2%, selling 3,124 shares and leaving it with 8,796 shares worth about $9.45 million, which represents 2.6% of the fund and its fifth-largest holding.
• Eli Lilly posted a strong Q1, beating EPS ($8.55 vs. $6.97) and revenue ($19.8B vs. $17.82B), showing 55.5% YoY revenue growth and setting FY2026 guidance of $35.50–$37.00 EPS, supporting bullish analyst upgrades.
• Management declared a $1.73 quarterly dividend (0.7% yield), while investor sentiment is broadly positive (consensus "Moderate Buy" with a ~$1,217 price target) but faces near-term risks from reported Foundayo liver events and competitive/pricing pressure from rivals.

Core Alternative Capital lowered its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 26.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,796 shares of the company's stock after selling 3,124 shares during the quarter. Eli Lilly and Company accounts for 2.6% of Core Alternative Capital's investment portfolio, making the stock its 5th biggest position. Core Alternative Capital's holdings in Eli Lilly and Company were worth $9,453,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Exencial Wealth Advisors LLC lifted its stake in shares of Eli Lilly and Company by 189.6% during the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock worth $13,283,000 after purchasing an additional 11,396 shares in the last quarter. Rede Wealth LLC acquired a new position in shares of Eli Lilly and Company during the third quarter worth about $487,000. Cidel Asset Management Inc. lifted its stake in shares of Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after purchasing an additional 5,591 shares in the last quarter. Spire Wealth Management lifted its stake in shares of Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company's stock worth $29,789,000 after purchasing an additional 592 shares in the last quarter. Finally, Coldstream Capital Management Inc. lifted its stake in shares of Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock worth $32,365,000 after purchasing an additional 8,659 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 2.2%

Shares of Eli Lilly and Company stock opened at $989.02 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a market cap of $931.40 billion, a P/E ratio of 35.13, a P/E/G ratio of 1.07 and a beta of 0.48. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The business has a 50-day moving average price of $946.66 and a 200 day moving average price of $988.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company's quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.39 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's payout ratio is currently 24.58%.

Wall Street Analyst Weigh In

A number of brokerages have commented on LLY. TD Cowen boosted their price objective on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a "buy" rating in a research note on Thursday, January 29th. Wall Street Zen upgraded Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Saturday. UBS Group reiterated a "buy" rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Finally, Leerink Partners cut their price target on Eli Lilly and Company from $1,296.00 to $1,058.00 and set an "outperform" rating on the stock in a research note on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,217.59.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong fundamentals: Q1 results and revenue beat underscore momentum in GLP‑1 franchise (Mounjaro/Foundayo) and underpin raised guidance. Eli Lilly Stock (LLY) Opinions on Q1 Earnings and Foundayo Safety Report
• Positive Sentiment: Foundayo commercial launch is off to a fast start — broad pharmacy access and payer coverage are driving new prescribers and patient uptake, supporting near‑term sales growth for Lilly. Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
• Positive Sentiment: Durable clinical readthrough: New long‑term data show Omvoh (mirikizumab) maintained disease clearance in ulcerative colitis at four years — a meaningful validation for Lilly’s immunology portfolio and future revenue stability. Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
• Positive Sentiment: Wall Street backing: Multiple firms have raised price targets and reiterated outperform/buy ratings (examples include Barclays and Wolfe Research), which supports investor sentiment and provides upside catalysts. Barclays/Wolfe coverage and price target updates
• Neutral Sentiment: Dividend: Lilly declared a $1.73 quarterly dividend (payable June 10), a modest yield that is shareholder‑friendly but not a major valuation driver. Lilly declares second-quarter 2026 dividend
• Negative Sentiment: Safety headwind: The FDA has logged serious liver events in patients taking Foundayo, which sparked a short‑term share dip and ongoing safety monitoring risk that could slow uptake or trigger label/payer scrutiny. FDA Reports Liver Failure in Patient Taking Lilly's Foundayo
• Negative Sentiment: Competitive/pricing pressure: Novo Nordisk’s oral pill momentum and talk of a price war raise margin and market‑share risk for all GLP‑1 players, keeping pricing dynamics a key watch item for Lilly. Novo Nordisk Faces Price War as Weight-Loss Pill Demand Rises

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.